ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform-Reference-Cited by-同舟云学术

ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform

Published:2013-10-15 Issue:20 Volume:12 Page:3298-3306
ISSN:1538-4101
Container-title:Cell Cycle
language:en
Short-container-title:Cell Cycle

Author:

Friboulet Luc,Postel-Vinay Sophie,Sourisseau Tony,Adam Julien,Stoclin Annabelle,Ponsonnailles Florence,Dorvault Nicolas,Commo Frédéric,Saulnier Patrick,Salome-Desmoulez Sophie,Pottier Géraldine,André Fabrice,Kroemer Guido,Soria Jean Charles,Olaussen Ken André

Publisher

Informa UK Limited

Subject

Cell Biology,Developmental Biology,Molecular Biology

Link

http://www.tandfonline.com/doi/pdf/10.4161/cc.26309

Reference33 articles.

1. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression

2. The Structure-Specific Endonuclease Ercc1-Xpf Is Required To Resolve DNA Interstrand Cross-Link-Induced Double-Strand Breaks

3. XPF-ERCC1 Participates in the Fanconi Anemia Pathway of Cross-Link Repair

4. Structure-Specific Endonucleases Xpf and Mus81 Play Overlapping but Essential Roles in DNA Repair by Homologous Recombination

5. Physical and Functional Interaction between the XPF/ERCC1 Endonuclease and hRad52

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cisplatin in the era of PARP inhibitors and immunotherapy;Pharmacology & Therapeutics;2024-06

2. Polyploidy in Cancer: Causal Mechanisms, Cancer-Specific Consequences, and Emerging Treatments;Molecular Cancer Therapeutics;2024-02-05

3. Mechanisms of chemotherapy resistance in cervical cancer;Strategies for Overcoming Chemotherapy Resistance in Cervical Cancer;2024

4. Insights into therapy resistance in cervical cancer;Advances in Cancer Biology - Metastasis;2022-12

5. Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology;Cancer Treatment Reviews;2022-03